Gilead Sciences
GILD
76.510
USD
0.47
(0.62%)
مغلق
حجم التداول
250,879
الربح لكل سهم
0
العائد الربحي
0
P/E
105
حجم السوق
107,430,366,669
أصول ذات صلة
الأخبار
المقالات
العنوان: Gilead Sciences
القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).